QuickCool AB (publ) signs distribution agreements for Spain
QuickCool AB (publ) (”QuickCool”) has signed a distribution agreement for Spain with Proyectos Hospitalarios Internacional S.A. (PRHOINSA).
PRHOINSA has a well-established network of Key Opinion Leaders (KOLs) and customers in Spain. This is QuickCool’s third distribution agreement. Preparatory sales activities start immediately, but no sales will occur until after the QuickCool® SYSTEM has acquired the CE-mark.
QuickCool, that develops a patented intranasal cooling solution for patients who have suffered from sudden cardiac arrest, has signed its third distribution agreement. This time for the Spanish market with PRHOINSA.
”I have good experiences from working with PRHOINSA in the past, so it was natural to contact them to see whether we could find a mutually agreeable business model for the sales, after-sales and training of our QuickCool® SYSTEM ”, says Fredrik Radencrantz, CEO at QuickCool.
“PRHOINSA was founded in 1999 and it is most appropriate to launch QuickCool® SYSTEM next year, when we celebrate two decades of successful sales within healthcare in Spain”, Alberto del Corro García-Lomas, Founder and General Manager at PRHOINSA, says.
“At PRHOINSA we continue to expand our product and service portfolio, particularly within intensive care. The QuickCool® SYSTEM becomes a differentiator in the project, turnkey and tender processes, where we are already successful. We find the QuickCool® SYSTEM to complement products such as the oesophageal and transpulmonary pressure measurement catheters, neuromuscular monitors and stimulators, in these larger tenders and projects. Our established sales representatives will also conduct direct sales to the ICU wards. It is an attractive solution to present and sell. It will save many lives and improve the quality of life of survivors of sudden cardiac arrest in Spain”, says Juan Carlos Herrero, Director Sales and Marketing at PRHOINSA.
Proyectos Hospitalarios Internacional S.A. (PRHOINSA)
PRHOINSA was established in 1999 and has a wide range of products and many years of experience of addressing the healthcare market in Spain – both in large tenders as well as direct sales. Regional sales representatives cover the whole Spanish market, with special emphasis on the more established areas of Madrid, Toledo, Barcelona, Sevilla, Alicante and Valencia. Dedicated service and training professionals ensure both clinical and product training and after sales support.
For more information, please contact:
Fredrik Radencrantz, VD
Telefon: 046-286 38 40
This information is such that QuickCool AB is required to make public in accordance with the EU’s market abuse regulation (MAR) and the Swedish Securities Market Act. The information was made publicly available, by the Company’s contact person, on 08 November, 2018.
Quickcool is a Swedish medical technology company, whose business concept is to save lives and prevent brain damage in acute ischemia (Inadequate blood supply to the brain) by developing and providing a unique and globally patented cooling system, the Quickcool SYSTEM. Quickcool is active in the fast-growing market, Targeted Temperature Management (TTM), for brain-protective cooling treatment of patients with e.g. acute cardiac arrest and stroke. QuickCool’s solution protects the brain by cooling in the nasal cavity and thus takes advantage of the innate heat exchanger in the nose. QuickCool’s Intranasal method offers gentle and uninterrupted cooling treatment for sedated patients. Quickcool is listed on Spotlight Stock Market and conducts its business at Ideon Science Park in Lund. For more Information, please refer to www.quickcool.se